Adial Pharmaceuticals Reports 2026 Second Quarter Financial Results and Provides Business Update
Adial Pharmaceuticals reported its Q2 2026 financial results, highlighting the completed acquisition of Azora Therapeutics which adds AT177, a colon-targeted treatment for ulcerative colitis, to its pipeline. The company strengthened its balance sheet by closing the initial $32 million tranche of a $64 million private placement, increasing cash to $28.7 million and extending its runway into the second half of 2027.
Key figures
- Cash
- 28700000
- Net loss
- 52000000
- Gna expense
- 5400000
- Rnd expense
- 440000
- Iprd expense
- 46200000
- Financing tranche closed
- 32000000
- Total placement potential
- 64000000
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.